Arizona Tribune - Boulevard

NYSE - LSE

NGG	0.66%	83.51	$
GSK	-0.16%	52.41	$
CMSC	-0.53%	21.93	$
RBGPF	0.33%	61.5	$
BCC	-2.6%	78.83	$
RELX	0.43%	31.475	$
BP	1.43%	37.659	$
RIO	0.74%	94.36	$
CMSD	0.68%	21.92	$
AZN	0.5%	189.16	$
RYCEF	4%	18.75	$
BCE	-1.51%	22.585	$
BTI	-0.52%	62.445	$
VOD	-1.17%	13.73	$
JRI	-0.08%	12.785	$

Featured

Chavez-era housing complex in ruins after Venezuela quakes

A residential complex once touted as part of former strongman leader Hugo Chavez's flagship housing program has been left uninhabitable in Venezuela's earthquake disaster.

Catholic traditionalists risk schism in Church

The Society of Saint Pius X, a traditionalist Catholic community, plans to ordain its own bishops on Wednesday without Vatican approval, raising the risk of schism within the Church.

Last news

Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association

Collaboration with USEA for Zomedica's PulseVet® shock wave system will increase brand awareness among Eventing enthusiasts.

InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 20

InterContinental Hotels Group PLC (the "Company")Purchase of own shares

Shock and bafflement at San Diego mosque where three were killed

Outside the San Diego mosque where his father was gunned down by heavily armed teenagers who had been radicalized online, Ramzy sits and stares blankly.

Google wants its search bar to act on your behalf in AI revamp

Google on Tuesday showed off new plans to turn its famous search bar into an AI assistant that can book restaurants, track news and contact businesses -- just by asking a question.

Pakistan court sentences man to death for killing teen influencer

A Pakistani court sentenced a man to death on Tuesday for murdering a teenage influencer last year after she had repeatedly rejected his advances.

Mango founder's son arrested in Spain over father's death

Spanish police said Tuesday they have arrested the eldest son of Mango clothing empire founder Isak Andic over his father's death during a hiking trip in December 2024.

US police investigating deadly mosque shooting as hate crime

Police were investigating a shooting in the US state of California as a hate crime on Tuesday after a pair of teenage gunmen killed three people at a mosque complex.

Government encourages women to report rape in French star's assault probes

The French government spokeswoman on Tuesday encouraged women to speak out about sexual violence, "even decades later," as she addressed mounting allegations of rape and assault targeting popular singer and actor Patrick Bruel.

Three killed in San Diego mosque shooting, both suspects dead

A shooting Monday at a mosque complex in southern California killed three people, with two suspected teenage gunmen later found dead in a car from apparent self-inflicted gunshot wounds, police said.

Campaigners warn Italy's gutted rape bill could help assailants

An attempt in Italy to introduce a consent-based rape law is floundering and experts warn rapists could stand to gain after the far right torpedoed an "only yes means yes" definition.

Libyan ex-prison boss faces ICC war crimes hearing

A former boss of a notorious Libyan prison faces three days of hearings at the International Criminal Court from Tuesday, accused of war crimes including murder, rape and torture.

Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'

His face smiles out from every kiosk in Rome on the cover of the ubiquitous "sexy priest" calendar sold to tourists but Giovanni Galizia was never a man of the cloth.

Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated April 28, 2026, continued progress in the intermediate1 scale-up and process development activities for the A83 and B4 precursor components supporting the Company's lead oncology program, ONC010, a novel nanoparticle-formulated PNKP inhibitor currently advancing through IND-enabling development.

Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update

Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited resultsQ1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient livesStrategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in PittsburghThe Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilitiesCompany has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions

Squeeze Launches PeelVoice to Bring Full-Funnel Visibility to Customer Conversations

New conversation intelligence platform helps marketing, sales, QA, and leadership teams turn every call into clearer insight, smarter action, and measurable performance improvement.

Bouka Family Sets Out Again to Conquer Everest

Inspiring resilience

Trustpoint Xposure Trustpoint Xposure Establishes New York Headquarters, Positioning the AEO-Certified PR Agency at the Center of the AI Search Revolution

The only PR agency that guarantees brand placement inside AI-generated answers brings its full methodology to New York, the most competitive professional market in the world.

Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies developing therapies targeting Clostridioides difficile infection (CDI), as the U.S. Food and Drug Administration finalized updated guidance that may significantly streamline the path toward approval for new CDI antibiotics.

Herbert Hoover Presidential Library and Museum to Celebrate Grand Reopening August 6, 2026

WEST BRANCH, IA / ACCESS Newswire / May 19, 2026 / The Hoover Presidential Foundation announced today the grand reopening of the newly renovated Herbert Hoover Presidential Library and Museum on Thursday, August 6, 2026, in West Branch, Iowa.

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants.

AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform

Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation.

Medical Care Technologies (OTC PINK:MDCE) Positions Its Next-Generation AI Strategy Amid Rapid Breakthroughs from NVIDIA and Anthropic

Rapid advances in artificial intelligence may create new opportunities for MDCE to expand technical capability while accelerating execution across its AI platform initiatives.

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's® commercially available Wegovy® tablets (the "Study").

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and no approved therapies, requiring lifelong parenteral support (PS)

CLS Health Helps Child Born with Three Rare Conditions to Walk Normally

A case study from the Houston region's leading physician-owned healthcare group delivered a life-changing intervention for a child born with a rare combination of Moebius syndrome, Poland syndrome and severe clubfoot.

Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption

Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe

Empirical Spine Announces First Commercial LimiFlex(R) Cases at Stanford Medicine, Marking U.S. Launch of Motion-Preserving Alternative to Fusion for Degenerative Spondylolisthesis

First U.S. commercial cases establish LimiFlex as an outpatient, motion-preserving stabilization option

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operating model concentrating resources and expertise on PT00114's Phase 2 advancement while positioning the Company for long-term value creation for patients and shareholders.

Off The Hook YS To Rebrand as NextBoat and Change Ticker Symbol to "NXB"

WILMINGTON, NC / ACCESS Newswire / May 19, 2026 / Off The Hook YS Inc. (NYSE American:OTH) ("Off the Hook Yachts" or "Off the Hook" or "the Company"), a vertically integrated, AI-powered marine marketplace and one of the largest buyers and sellers of used boats in the United States, today announced that it will officially rebrand as NextBoat Inc. and change its ticker symbol from "OTH" to "NXB" on the NYSE American, effective on or about May 29, 2026.

Black Book Research Releases State of Digital Healthcare IT 2026: Norway Market Report

New report analyzes Norway's digital health infrastructure, EHR modernization, national e-health platforms, interoperability, AI, cybersecurity, municipal care technology, and healthcare IT vendor landscape through 2030

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its Semaglutide oral dissolvable film ("ODF") program has entered the active pharmaceutical development phase in collaboration with German drug development partner Gen-Plus GmbH.

InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 19

Purchase of own shares

Arizona Tribune - Boulevard (English)